Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Novo Holdings Completes Regulatory Hurdles for Catalent Acquisition | Contract Pharma

What are you searching for?

Sign in
Breaking News

Novo Holdings Completes Regulatory Hurdles for Catalent Acquisition

The acquisition is expected to be completed in the coming days.

Author Image

By: Charlie Sternberg

Associate Editor, Contract Pharma

After receiving a green light from both U.S. and EU antitrust regulators, all regulatory closing conditions relating to the review of Novo Holdings A/S’s pending acquisition of Catalent Inc. have been fulfilled. The parties are now free to close the transaction, as well as Novo Nordisk’s subsequent acquisition of three Catalent manufacturing sites from Novo Holdings A/S.
 
The acquisition of Catalent is part of Novo Nordisk’s broader strategy to expand its manufacturing capabilities and secure supply chain resilience. By integrating Catalent’s extensive network of facilities and expertise, Novo Nordisk aims to enhance its ability to deliver innovative therapies to patients worldwide.  
 
As previously announced, Novo Nordisk also plans to acquire three Catalent manufacturing sites from Novo Holdings A/S. This additional acquisition is expected to further strengthen Novo Nordisk’s manufacturing footprint and operational efficiency.  
 
While the acquisition is expected to positively impact Novo Nordisk’s long-term growth, it will have a short-term impact on the company’s financial performance. The company anticipates a low single-digit negative impact on operating profit growth in 2024 and a mid single-digit negative impact in 2025. Additionally, the acquisition will increase the company’s debt levels and negatively impact net financial items.

Other Pharma Industry Acquisitions

Check out Contract Pharma’s 2024 Pharmaceutical Industry Mergers & Acquisitions Roundup.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics